Search Results - "MARU, Dipen"

Endothelial Cells Promote the Colorectal Cancer Stem Cell Phenotype through a Soluble Form of Jagged-1 by Lu, Jia, Ye, Xiangcang, Fan, Fan, Xia, Ling, Bhattacharya, Rajat, Bellister, Seth, Tozzi, Federico, Sceusi, Eric, Zhou, Yunfei, Tachibana, Isamu, Maru, Dipen M., Hawke, David H., Rak, Janusz, Mani, Sendurai A., Zweidler-McKay, Patrick, Ellis, Lee M.

“…We report a paracrine effect whereby endothelial cells (ECs) promote the cancer stem cell (CSC) phenotype of human colorectal cancer (CRC) cells. We showed…”
Get full text

Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes by Loree, Jonathan M, Pereira, Allan A L, Lam, Michael, Willauer, Alexandra N, Raghav, Kanwal, Dasari, Arvind, Morris, Van K, Advani, Shailesh, Menter, David G, Eng, Cathy, Shaw, Kenna, Broaddus, Russell, Routbort, Mark J, Liu, Yusha, Morris, Jeffrey S, Luthra, Rajyalakshmi, Meric-Bernstam, Funda, Overman, Michael J, Maru, Dipen, Kopetz, Scott

“…Colorectal cancers are classified as right/left-sided based on whether they occur before/after the splenic flexure, with established differences in molecular…”
Get full text

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis by Wang, Yinghong, Wiesnoski, Diana H., Helmink, Beth A., Gopalakrishnan, Vancheswaran, Choi, Kati, DuPont, Hebert L., Jiang, Zhi-Dong, Abu-Sbeih, Hamzah, Sanchez, Christopher A., Chang, Chia-Chi, Parra, Edwin R., Francisco-Cruz, Alejandro, Raju, Gottumukkala S., Stroehlein, John R., Campbell, Matthew T., Gao, Jianjun, Subudhi, Sumit K., Maru, Dipen M., Blando, Jorge M., Lazar, Alexander J., Allison, James P., Sharma, Padmanee, Tetzlaff, Michael T., Wargo, Jennifer A., Jenq, Robert R.

“…We report the first case series of immune checkpoint inhibitors (ICI)-associated colitis successfully treated with fecal microbiota transplantation, with…”
Get full text

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer by Tran, Ben, Kopetz, Scott, Tie, Jeanne, Gibbs, Peter, Jiang, Zhi‐Qin, Lieu, Christopher H., Agarwal, Atin, Maru, Dipen M., Sieber, Oliver, Desai, Jayesh

“…BACKGROUND: It is hypothesized that BRAF mutant cancers represent a discrete subset of metastatic colorectal cancer (CRC) defined by poorer survival. This…”
Get full text

RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases by Vauthey, Jean-Nicolas, Zimmitti, Giuseppe, Kopetz, Scott E., Shindoh, Junichi, Chen, Su S., Andreou, Andreas, Curley, Steven A., Aloia, Thomas A., Maru, Dipen M.

“…OBJECTIVE:To determine the impact of RAS mutation status on survival and patterns of recurrence in patients undergoing curative resection of colorectal liver…”
Get full text

Single-cell DNA sequencing reveals a late-dissemination model in metastatic colorectal cancer by Leung, Marco L, Davis, Alexander, Gao, Ruli, Casasent, Anna, Wang, Yong, Sei, Emi, Vilar, Eduardo, Maru, Dipen, Kopetz, Scott, Navin, Nicholas E

“…Metastasis is a complex biological process that has been difficult to delineate in human colorectal cancer (CRC) patients. A major obstacle in understanding…”
Get full text

RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases by Brudvik, Kristoffer Watten, Mise, Yoshihiro, Chung, Michael Hsiang, Chun, Yun Shin, Kopetz, Scott E., Passot, Guillaume, Conrad, Claudius, Maru, Dipen M., Aloia, Thomas A., Vauthey, Jean-Nicolas

“…Background In patients undergoing resection of colorectal liver metastases (CLM), resection margin status is a significant predictor of survival, particularly…”
Get full text

TP53 loss creates therapeutic vulnerability in colorectal cancer by Liu, Yunhua, Zhang, Xinna, Han, Cecil, Wan, Guohui, Huang, Xingxu, Ivan, Cristina, Jiang, Dahai, Rodriguez-Aguayo, Cristian, Lopez-Berestein, Gabriel, Rao, Pulivarthi H., Maru, Dipen M., Pahl, Andreas, He, Xiaoming, Sood, Anil K., Ellis, Lee M., Anderl, Jan, Lu, Xiongbin

“…Genomic deletion of the tumour suppressor TP53 frequently includes other neighbouring genes, such as the POLR2A housekeeping gene that encodes a crucial RNA…”
Get full text

Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer by Mehrvarz Sarshekeh, Amir, Advani, Shailesh, Overman, Michael J, Manyam, Ganiraju, Kee, Bryan K, Fogelman, David R, Dasari, Arvind, Raghav, Kanwal, Vilar, Eduardo, Manuel, Shanequa, Shureiqi, Imad, Wolff, Robert A, Patel, Keyur P, Luthra, Raja, Shaw, Kenna, Eng, Cathy, Maru, Dipen M, Routbort, Mark J, Meric-Bernstam, Funda, Kopetz, Scott

“…SMAD4 is an essential mediator in the transforming growth factor-β pathway. Sporadic mutations of SMAD4 are present in 2.1-20.0% of colorectal cancers (CRCs)…”
Get full text

Tumor Location Is a Strong Predictor of Tumor Progression and Survival in T2 Gallbladder Cancer: An International Multicenter Study by Shindoh, Junichi, de Aretxabala, Xabier, Aloia, Thomas A, Roa, Juan Carlos, Roa, Ivan, Zimmitti, Giuseppe, Javle, Milind, Conrad, Claudius, Maru, Dipen M, Aoki, Taku, Vigano, Luca, Ribero, Dario, Kokudo, Norihiro, Capussotti, Lorenzo, Vauthey, Jean-Nicolas

“…OBJECTIVE:To determine the prognostic impact of tumor location in gallbladder cancer. BACKGROUND:Depth of tumor is a strong predictor of survival after…”
Get full text

Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer by Azad, Tej D., Chaudhuri, Aadel A., Fang, Penny, Qiao, Yawei, Esfahani, Mohammad S., Chabon, Jacob J., Hamilton, Emily G., Yang, Yi D., Lovejoy, Alex, Newman, Aaron M., Kurtz, David M., Jin, Michael, Schroers-Martin, Joseph, Stehr, Henning, Liu, Chih Long, Hui, Angela Bik-Yu, Patel, Viren, Maru, Dipen, Lin, Steven H., Alizadeh, Ash A., Diehn, Maximilian

“…Biomarkers are needed to risk stratify after chemoradiotherapy for localized esophageal cancer. These could improve identification of patients at risk for…”
Get full text

Optimal Morphologic Response to Preoperative Chemotherapy: An Alternate Outcome End Point Before Resection of Hepatic Colorectal Metastases by SHINDOH, Junichi, LOYER, Evelyne M, VAUTHEY, Jean-Nicolas, KOPETZ, Scott, BOONSIRIKAMCHAI, Piyaporn, MARU, Dipen M, SHIN CHUN, Yun, ZIMMITTI, Giuseppe, CURLEY, Steven A, CHARNSANGAVEJ, Chusilp, ALOIA, Thomas A

“…The purposes of this study were to confirm the prognostic value of an optimal morphologic response to preoperative chemotherapy in patients undergoing…”
Get full text

Margin Status Remains an Important Determinant of Survival After Surgical Resection of Colorectal Liver Metastases in the Era of Modern Chemotherapy by Andreou, Andreas, Aloia, Thomas A, Brouquet, Antoine, Dickson, Paxton V, Zimmitti, Giuseppe, Maru, Dipen M, Kopetz, Scott, Loyer, Evelyne M, Curley, Steven A, Abdalla, Eddie K, Vauthey, Jean-Nicolas

“…OBJECTIVE:To determine the impact of surgical margin status on overall survival (OS) of patients undergoing hepatectomy for colorectal liver metastases after…”
Get full text

Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis by Xi, Mian, Xu, Cai, Liao, Zhongxing, Chang, Joe Y., Gomez, Daniel R., Jeter, Melenda, Cox, James D., Komaki, Ritsuko, Mehran, Reza, Blum, Mariela A., Hofstetter, Wayne L., Maru, Dipen M., Bhutani, Manoop S., Lee, Jeffrey H., Weston, Brian, Ajani, Jaffer A., Lin, Steven H.

“…To compare clinical outcomes between proton beam therapy (PBT) and intensity modulated radiation therapy (IMRT) in patients with esophageal cancer (EC) treated…”
Get full text

Exploratory study of macrophage polarization and spatial distribution in colorectal cancer liver metastasis: a pilot study by Khanduri, Isha, Maru, Dipen M., Parra, Edwin R.

“…BackgroundThe liver is the most typical site of metastatic disease for patients with colorectal cancer (CRC), and up to half the patients with CRC will develop…”
Get full text

Hippo Coactivator YAP1 Upregulates SOX9 and Endows Esophageal Cancer Cells with Stem-like Properties by SHUMEI SONG, AJANI, Jaffer A, LEE, Jeffrey H, WADHWA, Roopma, SUDO, Kazuki, STROEHLEIN, John R, MARTIN, James F, HUNG, Mien-Chie, JOHNSON, Randy L, HONJO, Soichiro, MARU, Dipen M, QIONGRONG CHEN, SCOTT, Ailing W, HEALLEN, Todd R, LIANCHUN XIAO, HOFSTETTER, Wayne L, WESTON, Brian

“…Cancer stem cells (CSC) are purported to initiate and maintain tumor growth. Deregulation of normal stem cell signaling may lead to the generation of CSCs;…”
Get full text

Multi-institutional Analysis of Recurrence and Survival After Neoadjuvant Chemoradiotherapy of Esophageal Cancer: Impact of Histology on Recurrence Patterns and Outcomes by Xi, Mian, Yang, Yadi, Zhang, Li, Yang, Hong, Merrell, Kenneth W., Hallemeier, Christopher L., Shen, Robert K., Haddock, Michael G., Hofstetter, Wayne L., Maru, Dipen M., Ho, Linus, Wu, Carol C., Liu, Mengzhong, Lin, Steven H.

“…OBJECTIVE:To determine the impact of histology on pathologic response, survival outcomes, and recurrence patterns in patients with esophageal cancer (EC) who…”
Get full text

TP53 Alteration and Its Effect on Pathologic Response Are Associated with Survival after Resection of Colorectal Liver Metastases by Maki, Harufumi, Haddad, Antony, Ayabe, Reed I., Lendoire, Mateo, Khanduri, Isha, Maru, Dipen M., Vauthey, Jean-Nicolas

“…The aims of this study were to assess the effect of known gene alterations (RAS, TP53, APC, SMAD4, BRAF, and FBXW7) on pathologic response (PR) and their…”
Get full text

Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases by Chun, Yun Shin, Vauthey, Jean-Nicolas, Boonsirikamchai, Piyaporn, Maru, Dipen M, Kopetz, Scott, Palavecino, Martin, Curley, Steven A, Abdalla, Eddie K, Kaur, Harmeet, Charnsangavej, Chusilp, Loyer, Evelyne M

“…CONTEXT The standard criteria used to evaluate tumor response, the Response Evaluation Criteria in Solid Tumors (RECIST), were developed to assess tumor…”
Get full text

Phase II Trial of Neoadjuvant Bevacizumab, Capecitabine, and Radiotherapy for Locally Advanced Rectal Cancer by Crane, Christopher H., M.D, Eng, Cathy, M.D, Feig, Barry W., M.D, Das, Prajnan, M.D, Skibber, John M., M.D, Chang, George J., M.D, Wolff, Robert A., M.D, Krishnan, Sunil, M.D, Hamilton, Stanley, M.D, Janjan, Nora A., M.D, Maru, Dipen M., M.D, Ellis, Lee M., M.D, Rodriguez-Bigas, Miguel A., M.D

“…Purpose We designed this Phase II trial to assess the efficacy and safety of the addition of bevacizumab to concurrent neoadjuvant capecitabine-based…”
Get full text